Loading…
Adaptive Biotechnologies Corporation is projected to rise to $33.82 by 2027, a +40% move from its current price of $24.18. ADPT is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $23.41 | $24.19 | $25.00 | +0.05% |
| Aug 2 | $23.10 | $24.20 | $25.36 | +0.10% |
| Aug 3 | $22.87 | $24.22 | $25.64 | +0.15% |
| Aug 4 | $22.68 | $24.23 | $25.88 | +0.20% |
| Aug 5 | $22.52 | $24.24 | $26.09 | +0.25% |
| Aug 6 | $22.37 | $24.25 | $26.29 | +0.29% |
| Aug 7 | $22.24 | $24.26 | $26.47 | +0.34% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $22.24 | $24.26 | $26.47 | +0.34% |
| Week 2 | $21.53 | $24.35 | $27.54 | +0.69% |
| Week 3 | $21.01 | $24.43 | $28.41 | +1.03% |
| Week 4 | $20.60 | $24.51 | $29.18 | +1.38% |
| Week 5 | $20.25 | $24.60 | $29.89 | +1.73% |
| Week 6 | $19.94 | $24.68 | $30.55 | +2.08% |
| Week 7 | $19.67 | $24.77 | $31.18 | +2.43% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Adaptive Biotechnologies Corporation is a healthcare company at the commercial stage that develops an immune medicine platform for the diagnosis and treatment of various diseases.
Adaptive offers an immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD).
The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. It was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Adaptive Biotechnologies Corporation (ADPT) is a healthcare company. It is currently priced at $22.90 per share and has a market cap of $3.67B, ranking 1616.
The near-term forecast shows a 2026 average price of $22.90 with a min of $12.41 and a max of $33.28, and sentiment for 2026 is NEUTRAL.
Longer-term projections indicate a bullish trajectory through 2030 and beyond, with 2027 avg $32.81, 2028 avg $37.78, 2029 avg $40.69, 2030 avg $47.25, 2031 avg $58.20, 2032 avg $79.52, 2033 avg $91.44, 2034 avg $97.41, 2035 avg $113.37, 2040 avg $205.97, and 2050 avg $376.77. Returns (ROI) in these years are 43.3%, 65.0%, 77.7%, 106.3%, 154.2%, 247.3%, 299.3%, 325.4%, 395.1%, 799.4%, and 1545.3%, with sentiment bullish from 2027 onward.
A major floor 48.7% below — a decisive break under it would weaken the trend.
The nearest floor, 30.6% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 20.4% above — clearing it would confirm fresh momentum.
Key ADPT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ADPT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $22.81 | Buy | $23.03 | Buy |
| MA 10 | $22.57 | Buy | $22.61 | Buy |
| MA 20 | $21.98 | Buy | $21.86 | Buy |
| MA 50 | $19.02 | Buy | $19.71 | Buy |
| MA 100 | $16.43 | Buy | $17.93 | Buy |
| MA 200 | $16.55 | Buy | $16.21 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 67.75 | Neutral |
| Stoch RSI (14) | 99.48 | Sell |
| CCI (20) | 208.00 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | -0.05 | Sell |
| ROC (12) | 12.75 | Buy |
| Bollinger %B (20,2) | 1.12 | Sell |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.86 | Buy |
| Awesome (5,34) | 2.07 | Buy |
| Ultimate (7,14,28) | 73.22 | Sell |
| Momentum (10) | 2.08 | Buy |
| Aroon Osc (25) | 100.00 | Buy |
| Hull MA (9) | 23.11 | Buy |
| ADX (14) | 25.28 | Buy |
| ATR (14) | 0.63 | Info |
30-day technical picture: sentiment is BULLISH, RSI14 is 60, SMA50 is $16.75, and SMA200 is $16.02. The price is above both moving averages, indicating a positive short-term trend. Support is at $15.14 and resistance at $22.37. The stock’s 30-day price range spans $17.90 to $29.30. Annualized volatility is 70%.
These technical levels provide a framework for the near-term price action, with momentum supported by the stated indicators.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $12.41 | $24.18 | $33.68 | 0% | Neutral | |
| $26.47 | $33.82 | $46.00 | +40% | Bullish | |
| $28.72 | $38.00 | $54.00 | +57% | Bullish | |
| $31.26 | $42.57 | $62.59 | +76% | Bullish | |
| $35.71 | $49.90 | $75.49 | +106% | Bullish | |
| $42.09 | $60.21 | $93.36 | +149% | Bullish | |
| $56.93 | $83.23 | $131.94 | +244% | Bullish | |
| $63.13 | $94.21 | $152.34 | +290% | Bullish | |
| $63.89 | $97.25 | $160.15 | +302% | Bullish | |
| $74.64 | $115.76 | $193.89 | +379% | Bullish | |
| $122.35 | $206.93 | $371.87 | +756% | Bullish | |
| $202.19 | $398.55 | $792.73 | +15.5x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $12.41 | $24.18 | $28.24 | +0.00% |
| August 2026 | $21.25 | $25.05 | $30.30 | +3.60% |
| September 2026 | $21.23 | $25.28 | $31.07 | +0.93% |
| October 2026 | $20.57 | $24.69 | $30.73 | -2.34% |
| November 2026 | $20.84 | $25.18 | $31.66 | +1.97% |
| December 2026 | $21.83 | $26.55 | $33.68 | +5.42% |
Click any year to see its month-by-month ADPT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The ADPT price prediction for 2026 points to an average of $24.18 (low $12.41, high $33.68) — a potential gain of 0% on today's $24.18. Price action looks broadly range-bound.
In 2027, ADPT is projected to trade between $26.47 and $46.00, averaging $33.82 — a potential gain of +40% from today's $24.18. That is up +40% on the projected 2026 average. Buyers look set to stay in control over this stretch.
Adaptive Biotechnologies Corporation's 2028 outlook centres on $38.00, within a $28.72 to $54.00 range. That is up +12% on the projected 2027 average. That marks a +57% change versus current levels. Momentum favours further upside here.
By 2029, ADPT could reach as high as $62.59, with a base case around $42.57 and support toward $31.26 — roughly +76% from $24.18. Buyers look set to stay in control over this stretch.
Expect ADPT to range from $35.71 to $75.49 through 2030. The $49.90 average target implies a +106% move from current prices. That is up +17% on the projected 2029 average. Momentum favours further upside here.
The ADPT price prediction for 2031 points to an average of $60.21 (low $42.09, high $93.36) — a potential gain of +149% on today's $24.18. Buyers look set to stay in control over this stretch.
In 2032, ADPT is projected to trade between $56.93 and $131.94, averaging $83.23 — a potential gain of +244% from today's $24.18. That is up +38% on the projected 2031 average. Momentum favours further upside here.
Adaptive Biotechnologies Corporation's 2033 outlook centres on $94.21, within a $63.13 to $152.34 range. That is up +13% on the projected 2032 average. That marks a +290% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, ADPT could reach as high as $160.15, with a base case around $97.25 and support toward $63.89 — roughly +302% from $24.18. Momentum favours further upside here.
Expect ADPT to range from $74.64 to $193.89 through 2035. The $115.76 average target implies a +379% move from current prices. That is up +19% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The ADPT price prediction for 2040 points to an average of $206.93 (low $122.35, high $371.87) — a potential gain of +756% on today's $24.18. Momentum favours further upside here.
In 2050, ADPT is projected to trade between $202.19 and $792.73, averaging $398.55 — a potential gain of +15.5x from today's $24.18. That is up +93% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in ADPT today (≈ 41.356493 ADPT) could be worth
$16,482.81
+$15,482.81 (+1548%) by 2050 · US Dollar
Based on the average projected ADPT price of $398.55 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ADPTwould be worth at today's price.
$1,000 invested in ADPT on Jul 30, 2025 (≈ 95.785444 ADPT) would be worth
$2,316.09
+$1,316.09 (+131.6%) today · 2.32× · US Dollar
Based on a ADPT entry price of $10.44 vs. today's $24.18.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $22.31 | $1,083.82 | +8.4% |
| 1 month ago | $21.45 | $1,127.27 | +12.7% |
| 3 months ago | $14.27 | $1,694.46 | +69.4% |
| 6 months ago | $18.5 | $1,307.03 | +30.7% |
| 1 year ago | $10.44 | $2,316.09 | +131.6% |
| All time (5.0y) ago | $36.79 | $657.24 | -34.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ADPT forecast.
Our base-case forecast reaches $48.00 around 2030.
Implied market cap at $48.00: $7.63B
The multi-year forecast portrays a sustained bullish trajectory with rising averages and substantial upside potential. From 2027 through 2035, the model projects average prices climbing from $32.81 to $113.37, with corresponding max values reaching $197.97 in 2035. The forecast for 2030 shows an average of $47.25, and the 2040 and 2050 projections rise to $205.97 and $376.77 respectively, with ROI figures of 106.3% and 1545.3% in those later years.
Across 2040 and 2050, the model indicates substantial upside, with max forecasts reaching $388.22 in 2040 and $792.23 in 2050. These figures accompany bullish sentiment throughout 2027–2050. These estimates are not guarantees and depend on future market conditions, but they outline a potential path for higher prices over the next decades.
Tap a question to reveal the answer.
2030: min $32.78, avg $47.25, max $73.83; ROI 106.3%; sentiment BULLISH.
The forecast shows bullish sentiment from 2027 onward with notable upside (e.g., 2027 avg $32.81; 2030 avg $47.25; 2040 avg $205.97; 2050 avg $376.77; ROI 43.3%, 106.3%, 799.4%, 1545.3%). Note 2026 is neutral.
Yes. The forecast max prices include $197.97 by 2035 and $388.22 by 2040, with $792.23 max by 2050.
The 30-day range is $17.90 to $29.30.
Current price is $22.90 and market cap is $3.67B; rank 1616.
Adaptive Biotechnologies Corporation Community Discussion
0Share your Adaptive Biotechnologies Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.